Pasithea Therapeutics -CW26KTTAWPreferred / convertible
13F holders, Q2 2024 (June 30)6holders
0new positions
0sold out
1famous investor
$0.02avg. 13F price*
At the end of Q2 2024, 6 institutions reported holding Pasithea Therapeutics -CW26 (KTTAW) in their 13F filings, unchanged from Q1 2024. 0 opened new positions and 0 sold out. The largest holders were Kepos Capital LP ($7K), Warberg Asset Management LLC ($4K) and Armistice Capital, LLC ($995). One famous investor held it Ken Griffin ( of Citadel Advisors's portfolio).
- Company
- Pasithea Therapeutics -CW26
- CUSIP
- 70261F111
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q1 2024 → Q2 2024: 11,199 shares sold, net −11,199 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 6 holders
| Kepos Capital LP | — | No change | 334,600 | $7K |
| Warberg Asset Management LLC | — | Reduce -3.9% | 278,684 | $4K |
| Armistice Capital, LLC | — | No change | 50,000 | $995 |
| Marex Group Ltd | — | No change | 25,000 | $275 |
| Citadel Advisors | — | Reduce -0.1% | 13,189 | $144 |
| UBS Group AG | — | No change | 34 | $0 |
"% of holder's portfolio" is KTTAW's weight in each manager's 13F, not the share of Pasithea Therapeutics -CW26 the manager owns.